Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial (Nature Medicine, (2023), 29, 3, (588-592), 10.1038/s41591-022-02199-y)

Jeroen van Dorp; Christodoulos Pipinikas; Britt B M Suelmann; Niven Mehra; Nick van Dijk; Giovanni Marsico; Maurits L van Montfoort; Sophie Hackinger; Linde M Braaf; Tauanne Amarante; Charlaine van Steenis; Kirsten McLay; Antonios Daletzakis; Daan van den Broek; Maaike W van de Kamp; Kees Hendricksen; Jeantine M de Feijter; Thierry N Boellaard; Richard P Meijer; Antoine G van der Heijden; Nitzan Rosenfeld; Bas W G van Rhijn; Greg Jones; Michiel S van der Heijden

doi:10.1038/s41591-023-02500-7

Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial (Nature Medicine, (2023), 29, 3, (588-592), 10.1038/s41591-022-02199-y)

Jeroen van Dorp, Christodoulos Pipinikas, Britt B M Suelmann, Niven Mehra, Nick van Dijk, Giovanni Marsico, Maurits L van Montfoort, Sophie Hackinger, Linde M Braaf, Tauanne Amarante, Charlaine van Steenis, Kirsten McLay, Antonios Daletzakis, Daan van den Broek, Maaike W van de Kamp, Kees Hendricksen, Jeantine M de Feijter, Thierry N Boellaard, Richard P Meijer, Antoine G van der HeijdenNitzan Rosenfeld, Bas W G van Rhijn, Greg Jones^*, Michiel S van der Heijden^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

1 Downloads (Pure)

Abstract

Correction to: Nature Medicine. Published online 2 February 2023. In the version of this article initially published, the first name of Antoine G. van der Heijden was misspelled as “Toine” and has now been corrected in the HTML and PDF versions of the article.

Original language	English
Pages (from-to)	304
Number of pages	1
Journal	Nature Medicine
Volume	30
Issue number	1
Early online date	17 Jul 2023
DOIs	https://doi.org/10.1038/s41591-023-02500-7
Publication status	Published - Jan 2024

Access to Document

10.1038/s41591-023-02500-7Licence: CC BY

s41591-023-02500-7Final published version, 503 KBLicence: CC BY

Fingerprint

Dive into the research topics of 'Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial (Nature Medicine, (2023), 29, 3, (588-592), 10.1038/s41591-022-02199-y)'. Together they form a unique fingerprint.

Cite this

van Dorp, J., Pipinikas, C., Suelmann, B. B. M., Mehra, N., van Dijk, N., Marsico, G., van Montfoort, M. L., Hackinger, S., Braaf, L. M., Amarante, T., van Steenis, C., McLay, K., Daletzakis, A., van den Broek, D., van de Kamp, M. W., Hendricksen, K., de Feijter, J. M., Boellaard, T. N., Meijer, R. P., ... van der Heijden, M. S. (2024). Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial (Nature Medicine, (2023), 29, 3, (588-592), 10.1038/s41591-022-02199-y). Nature Medicine, 30(1), 304. https://doi.org/10.1038/s41591-023-02500-7

@article{70cdb3c549594411a1387af2e996f179,

title = "Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial (Nature Medicine, (2023), 29, 3, (588-592), 10.1038/s41591-022-02199-y)",

abstract = "Correction to: Nature Medicine. Published online 2 February 2023. In the version of this article initially published, the first name of Antoine G. van der Heijden was misspelled as “Toine” and has now been corrected in the HTML and PDF versions of the article.",

author = "{van Dorp}, Jeroen and Christodoulos Pipinikas and Suelmann, {Britt B M} and Niven Mehra and {van Dijk}, Nick and Giovanni Marsico and {van Montfoort}, {Maurits L} and Sophie Hackinger and Braaf, {Linde M} and Tauanne Amarante and {van Steenis}, Charlaine and Kirsten McLay and Antonios Daletzakis and {van den Broek}, Daan and {van de Kamp}, {Maaike W} and Kees Hendricksen and {de Feijter}, {Jeantine M} and Boellaard, {Thierry N} and Meijer, {Richard P} and {van der Heijden}, {Antoine G} and Nitzan Rosenfeld and {van Rhijn}, {Bas W G} and Greg Jones and {van der Heijden}, {Michiel S}",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s), under exclusive licence to Springer Nature America, Inc.",

year = "2024",

month = jan,

doi = "10.1038/s41591-023-02500-7",

language = "English",

volume = "30",

pages = "304",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "1",

}

van Dorp, J, Pipinikas, C, Suelmann, BBM, Mehra, N, van Dijk, N, Marsico, G, van Montfoort, ML, Hackinger, S, Braaf, LM, Amarante, T, van Steenis, C, McLay, K, Daletzakis, A, van den Broek, D, van de Kamp, MW, Hendricksen, K, de Feijter, JM, Boellaard, TN, Meijer, RP, van der Heijden, AG, Rosenfeld, N, van Rhijn, BWG, Jones, G & van der Heijden, MS 2024, 'Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial (Nature Medicine, (2023), 29, 3, (588-592), 10.1038/s41591-022-02199-y)', Nature Medicine, vol. 30, no. 1, pp. 304. https://doi.org/10.1038/s41591-023-02500-7

Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial (Nature Medicine, (2023), 29, 3, (588-592), 10.1038/s41591-022-02199-y). / van Dorp, Jeroen; Pipinikas, Christodoulos; Suelmann, Britt B M et al.
In: Nature Medicine, Vol. 30, No. 1, 01.2024, p. 304.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Author Correction

T2 - High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial (Nature Medicine, (2023), 29, 3, (588-592), 10.1038/s41591-022-02199-y)

AU - van Dorp, Jeroen

AU - Pipinikas, Christodoulos

AU - Suelmann, Britt B M

AU - Mehra, Niven

AU - van Dijk, Nick

AU - Marsico, Giovanni

AU - van Montfoort, Maurits L

AU - Hackinger, Sophie

AU - Braaf, Linde M

AU - Amarante, Tauanne

AU - van Steenis, Charlaine

AU - McLay, Kirsten

AU - Daletzakis, Antonios

AU - van den Broek, Daan

AU - van de Kamp, Maaike W

AU - Hendricksen, Kees

AU - de Feijter, Jeantine M

AU - Boellaard, Thierry N

AU - Meijer, Richard P

AU - van der Heijden, Antoine G

AU - Rosenfeld, Nitzan

AU - van Rhijn, Bas W G

AU - Jones, Greg

AU - van der Heijden, Michiel S

PY - 2024/1

Y1 - 2024/1

N2 - Correction to: Nature Medicine. Published online 2 February 2023. In the version of this article initially published, the first name of Antoine G. van der Heijden was misspelled as “Toine” and has now been corrected in the HTML and PDF versions of the article.

AB - Correction to: Nature Medicine. Published online 2 February 2023. In the version of this article initially published, the first name of Antoine G. van der Heijden was misspelled as “Toine” and has now been corrected in the HTML and PDF versions of the article.

UR - http://www.scopus.com/inward/record.url?scp=85164955218&partnerID=8YFLogxK

U2 - 10.1038/s41591-023-02500-7

DO - 10.1038/s41591-023-02500-7

M3 - Comment/Letter to the editor

C2 - 37460757

SN - 1078-8956

VL - 30

SP - 304

JO - Nature Medicine

JF - Nature Medicine

IS - 1

ER -

van Dorp J, Pipinikas C, Suelmann BBM, Mehra N, van Dijk N, Marsico G et al. Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial (Nature Medicine, (2023), 29, 3, (588-592), 10.1038/s41591-022-02199-y). Nature Medicine. 2024 Jan;30(1):304. Epub 2023 Jul 17. doi: 10.1038/s41591-023-02500-7

Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial (Nature Medicine, (2023), 29, 3, (588-592), 10.1038/s41591-022-02199-y)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this